The subject of the present invention is to provide a novel crystal form of compound with activating clotting factor X inhibition, which is useful for a pharmaceutical compsotion for prophylaxis and/or treatment of thrombotic and/or embolic diseases. According to the present invention, it provides a novel crystal form of N1-(5-chloropyridin-2-ly)-N2-((1S,2R,4S) -4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-yl)carbonyl]amino}cyclohexyl)ethanediamide p-tosilate hydrate, and a preparation method thereof.本發明之課題係提供有用於作為血栓性及/或塞栓性疾病之預防及/或治療用之醫藥化合物之具有活化凝血因子X抑制作用的化合物之新穎結晶形。依據本發明，提供N1-(5-氯吡啶-2-基)-N2-((1S,2R,4S)-4-[(二甲基胺基)羰基]-2-{[(5-甲基-4,5,6,7-四氫噻唑并[5,4-c]吡啶-2-基)羰基]胺基}環己基)乙二醯胺p-甲苯磺酸鹽一水合物之新穎結晶形及其製造方法。
